• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>COPD: Journal of Chronic Obstructive Pulmonary Disease >TORCH and UPLIFT: what has been learned from the COPD 'mega-trials'?
【24h】

TORCH and UPLIFT: what has been learned from the COPD 'mega-trials'?

机译：火炬和升级：从COPD“大型试验”中学到了什么？

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

TORCH and UPLIFT are amongst the largest and most ambitious COPD trials ever undertaken. In terms of the primary outcomes, both trials were negative. Compared with placebo, combined salmeterol and fluticasone therapy did not significantly reduce all cause mortality over 3 years in TORCH, and tiotropium did not slow the decline in lung function over 4 years in UPLIFT. Secondary outcomes from these studies strongly confirmed findings from previous trials. Monotherapy with all three drugs provided small improvements in respiratory health status and reductions in exacerbation rates with some additive effect from the salmeterol/fluticasone combination. Both salmeterol/fluticasone and tiotropium also reduced COPD hospitalization rates. The trials provide very strong evidence that the long-acting bronchodilators, salmeterol and tiotropium, are not associated with increased risk of death or major cardiovascular adverse events.
机译：TORCH和UPLIFT是有史以来规模最大，最雄心勃勃的COPD试验之一。就主要结局而言，两项试验均为阴性。与安慰剂相比，沙美特罗和氟替卡松联合治疗并未显着降低TORCH治疗3年以上的所有病因死亡率，噻托溴铵在UPLIFT治疗4年内并未减缓肺功能下降。这些研究的次要结果强有力地证实了先前试验的发现。沙美特罗/氟替卡松联合使用这三种药物的单药疗法在呼吸健康状况方面有小幅改善，加重率降低，但有一定的加和作用。沙美特罗/氟替卡松和噻托溴铵也降低了COPD的住院率。该试验提供了非常有力的证据，证明长效支气管扩张剂沙美特罗和噻托溴铵与死亡风险增加或重大心血管不良事件无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号